Oxford Biomedica (LON:OXB) Issues Earnings Results

Oxford Biomedica (LON:OXB) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported GBX (41.75) (($0.54)) EPS for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative return on equity of 202.50% and a negative net margin of 145.98%.

Oxford Biomedica Stock Down 1.8 %

Shares of LON OXB opened at GBX 273.50 ($3.55) on Friday. The stock has a market capitalization of £290.73 million, a P/E ratio of -2.03 and a beta of 1.09. The stock’s fifty day moving average is GBX 319.38 and its 200 day moving average is GBX 379.08. Oxford Biomedica has a 52 week low of GBX 187.83 ($2.44) and a 52 week high of GBX 455 ($5.91). The company has a debt-to-equity ratio of 166.48, a quick ratio of 1.67 and a current ratio of 2.35.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.